Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus

Karen H. Costenbader, Elizabeth W. Karlson, Victoria Gall, Paola De Pablo, Axel Finckh, Marsha Lynch, Bonnie Bermas, Peter H. Schur, Matthew H. Liang

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objective. The effectiveness of aggressive management of traditional risk factors for accelerated atherosclerosis in systemic lupus erythematosus (SLE) has been advocated but not proven. We conducted a pilot, randomized, controlled trial of known prevention medications (pravastatin, ramipril, aspirin, and a combination B vitamin) plus individualized cardiovascular prevention education. We describe our experience in recruiting and retaining patients with SLE in this trial. Methods. Patients with SLE by American College of Rheumatology criteria who lived within 1 hour of the hospital and had visits within the past 3 years were screened. All eligible patients were contacted by the principal investigator who was not their physician. The reasons for nonparticipation were elicited in a nonjudgmental manner. Results. A total of 662 patients met the selection criteria for the study. Of these, 295 patients (45%) with contraindications to study medications were excluded. Ninety-seven (40%) of 244 eligible patients refused to participate. More than 40% of those phoned were unwilling to participate and, among those, 19% felt they were too sick, too well, or taking too many medications already. A total of 41 patients were enrolled in the trial, and 22 dropped out within 4 months. Conclusion. SLE is a chronic disease, and the development and testing of interventions aimed at the prevention of long-term sequelae are of paramount importance. Prevention trials in SLE face serious challenges, including the recruitment and retention of participants. Our experience provides insights into the barriers to participation in randomized prevention trials in SLE.

Original languageEnglish (US)
Pages (from-to)718-723
Number of pages6
JournalArthritis Care and Research
Volume53
Issue number5
DOIs
StatePublished - Oct 15 2005

Fingerprint

Systemic Lupus Erythematosus
Atherosclerosis
Patient Selection
Ramipril
Pravastatin
Vitamin B Complex
Aspirin
Chronic Disease
Randomized Controlled Trials
Research Personnel
Physicians
Education

Keywords

  • Atherosclerosis
  • Prevention
  • Systemic lupus erythematosus
  • Trial

ASJC Scopus subject areas

  • Rheumatology

Cite this

Costenbader, K. H., Karlson, E. W., Gall, V., De Pablo, P., Finckh, A., Lynch, M., ... Liang, M. H. (2005). Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Care and Research, 53(5), 718-723. https://doi.org/10.1002/art.21441

Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. / Costenbader, Karen H.; Karlson, Elizabeth W.; Gall, Victoria; De Pablo, Paola; Finckh, Axel; Lynch, Marsha; Bermas, Bonnie; Schur, Peter H.; Liang, Matthew H.

In: Arthritis Care and Research, Vol. 53, No. 5, 15.10.2005, p. 718-723.

Research output: Contribution to journalArticle

Costenbader, KH, Karlson, EW, Gall, V, De Pablo, P, Finckh, A, Lynch, M, Bermas, B, Schur, PH & Liang, MH 2005, 'Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus', Arthritis Care and Research, vol. 53, no. 5, pp. 718-723. https://doi.org/10.1002/art.21441
Costenbader KH, Karlson EW, Gall V, De Pablo P, Finckh A, Lynch M et al. Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Care and Research. 2005 Oct 15;53(5):718-723. https://doi.org/10.1002/art.21441
Costenbader, Karen H. ; Karlson, Elizabeth W. ; Gall, Victoria ; De Pablo, Paola ; Finckh, Axel ; Lynch, Marsha ; Bermas, Bonnie ; Schur, Peter H. ; Liang, Matthew H. / Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. In: Arthritis Care and Research. 2005 ; Vol. 53, No. 5. pp. 718-723.
@article{9e4992e6b85f4064bd79fe94cd50b245,
title = "Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus",
abstract = "Objective. The effectiveness of aggressive management of traditional risk factors for accelerated atherosclerosis in systemic lupus erythematosus (SLE) has been advocated but not proven. We conducted a pilot, randomized, controlled trial of known prevention medications (pravastatin, ramipril, aspirin, and a combination B vitamin) plus individualized cardiovascular prevention education. We describe our experience in recruiting and retaining patients with SLE in this trial. Methods. Patients with SLE by American College of Rheumatology criteria who lived within 1 hour of the hospital and had visits within the past 3 years were screened. All eligible patients were contacted by the principal investigator who was not their physician. The reasons for nonparticipation were elicited in a nonjudgmental manner. Results. A total of 662 patients met the selection criteria for the study. Of these, 295 patients (45{\%}) with contraindications to study medications were excluded. Ninety-seven (40{\%}) of 244 eligible patients refused to participate. More than 40{\%} of those phoned were unwilling to participate and, among those, 19{\%} felt they were too sick, too well, or taking too many medications already. A total of 41 patients were enrolled in the trial, and 22 dropped out within 4 months. Conclusion. SLE is a chronic disease, and the development and testing of interventions aimed at the prevention of long-term sequelae are of paramount importance. Prevention trials in SLE face serious challenges, including the recruitment and retention of participants. Our experience provides insights into the barriers to participation in randomized prevention trials in SLE.",
keywords = "Atherosclerosis, Prevention, Systemic lupus erythematosus, Trial",
author = "Costenbader, {Karen H.} and Karlson, {Elizabeth W.} and Victoria Gall and {De Pablo}, Paola and Axel Finckh and Marsha Lynch and Bonnie Bermas and Schur, {Peter H.} and Liang, {Matthew H.}",
year = "2005",
month = "10",
day = "15",
doi = "10.1002/art.21441",
language = "English (US)",
volume = "53",
pages = "718--723",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus

AU - Costenbader, Karen H.

AU - Karlson, Elizabeth W.

AU - Gall, Victoria

AU - De Pablo, Paola

AU - Finckh, Axel

AU - Lynch, Marsha

AU - Bermas, Bonnie

AU - Schur, Peter H.

AU - Liang, Matthew H.

PY - 2005/10/15

Y1 - 2005/10/15

N2 - Objective. The effectiveness of aggressive management of traditional risk factors for accelerated atherosclerosis in systemic lupus erythematosus (SLE) has been advocated but not proven. We conducted a pilot, randomized, controlled trial of known prevention medications (pravastatin, ramipril, aspirin, and a combination B vitamin) plus individualized cardiovascular prevention education. We describe our experience in recruiting and retaining patients with SLE in this trial. Methods. Patients with SLE by American College of Rheumatology criteria who lived within 1 hour of the hospital and had visits within the past 3 years were screened. All eligible patients were contacted by the principal investigator who was not their physician. The reasons for nonparticipation were elicited in a nonjudgmental manner. Results. A total of 662 patients met the selection criteria for the study. Of these, 295 patients (45%) with contraindications to study medications were excluded. Ninety-seven (40%) of 244 eligible patients refused to participate. More than 40% of those phoned were unwilling to participate and, among those, 19% felt they were too sick, too well, or taking too many medications already. A total of 41 patients were enrolled in the trial, and 22 dropped out within 4 months. Conclusion. SLE is a chronic disease, and the development and testing of interventions aimed at the prevention of long-term sequelae are of paramount importance. Prevention trials in SLE face serious challenges, including the recruitment and retention of participants. Our experience provides insights into the barriers to participation in randomized prevention trials in SLE.

AB - Objective. The effectiveness of aggressive management of traditional risk factors for accelerated atherosclerosis in systemic lupus erythematosus (SLE) has been advocated but not proven. We conducted a pilot, randomized, controlled trial of known prevention medications (pravastatin, ramipril, aspirin, and a combination B vitamin) plus individualized cardiovascular prevention education. We describe our experience in recruiting and retaining patients with SLE in this trial. Methods. Patients with SLE by American College of Rheumatology criteria who lived within 1 hour of the hospital and had visits within the past 3 years were screened. All eligible patients were contacted by the principal investigator who was not their physician. The reasons for nonparticipation were elicited in a nonjudgmental manner. Results. A total of 662 patients met the selection criteria for the study. Of these, 295 patients (45%) with contraindications to study medications were excluded. Ninety-seven (40%) of 244 eligible patients refused to participate. More than 40% of those phoned were unwilling to participate and, among those, 19% felt they were too sick, too well, or taking too many medications already. A total of 41 patients were enrolled in the trial, and 22 dropped out within 4 months. Conclusion. SLE is a chronic disease, and the development and testing of interventions aimed at the prevention of long-term sequelae are of paramount importance. Prevention trials in SLE face serious challenges, including the recruitment and retention of participants. Our experience provides insights into the barriers to participation in randomized prevention trials in SLE.

KW - Atherosclerosis

KW - Prevention

KW - Systemic lupus erythematosus

KW - Trial

UR - http://www.scopus.com/inward/record.url?scp=26844559974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844559974&partnerID=8YFLogxK

U2 - 10.1002/art.21441

DO - 10.1002/art.21441

M3 - Article

C2 - 16208639

AN - SCOPUS:26844559974

VL - 53

SP - 718

EP - 723

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 5

ER -